Normal view MARC view ISBD view

Bioresorbable scaffolds: rationale, current status, challenges, and future. [Review]

MedStar author(s):

Citation: European Heart Journal. 35(12):765-76, 2014 Mar.PMID: 24366915Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal Article | Research Support, Non-U.S. Gov't | ReviewSubject headings: *Absorbable Implants/td [Trends] | *Tissue Scaffolds/td [Trends] | Blood Vessel Prosthesis | Clinical Trials as Topic | Coronary Stenosis/th [Therapy] | Drug-Eluting Stents | Forecasting | Graft Occlusion, Vascular/pc [Prevention & Control] | Humans | Metals/tu [Therapeutic Use] | Prosthesis DesignYear: 2014 Local holdings: Available online from MWHC library: 1996 - present (after 1 year), Available in print through MWHC library: 1999 - 2006ISSN:

0195-668X

Name of journal: European heart journalAbstract: Current generation of drug-eluting stents has significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, and neoatherosclerosis. The permanent stents also indefinitely impair the physiological vasomotor function of the vessel and future potential of grafting the stented segment. Bioresorbable scaffolds (BRSs) have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress, and mechanotransduction. While a number of BRSs are under development, two devices with substantial clinical data have already received a Conformite Europeenne marking. This review article presents the current status of these devices and evaluates the challenges that need to be overcome before BRSs can become the workhorse device in coronary intervention.All authors: Abizaid A, Iqbal J, Onuma Y, Ormiston J, Serruys P, Waksman RFiscal year: FY2014Digital Object Identifier:

http://dx.doi.org/10.1093/eurheartj/eht542

Date added to catalog: 2015-03-17

Holdings ( 1 )
Title notes ( 3 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	24366915	Available		24366915

Available online from MWHC library: 1996 - present (after 1 year), Available in print through MWHC library: 1999 - 2006

Current generation of drug-eluting stents has significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, and neoatherosclerosis. The permanent stents also indefinitely impair the physiological vasomotor function of the vessel and future potential of grafting the stented segment. Bioresorbable scaffolds (BRSs) have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress, and mechanotransduction. While a number of BRSs are under development, two devices with substantial clinical data have already received a Conformite Europeenne marking. This review article presents the current status of these devices and evaluates the challenges that need to be overcome before BRSs can become the workhorse device in coronary intervention.

English